1. Home
  2. NVCR vs NVAX Comparison

NVCR vs NVAX Comparison

Compare NVCR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$10.98

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.46

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVCR
NVAX
Founded
2000
1987
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
NVCR
NVAX
Price
$10.98
$8.46
Analyst Decision
Buy
Hold
Analyst Count
6
9
Target Price
$28.08
$11.33
AVG Volume (30 Days)
1.3M
4.4M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
21.79
309.76
EPS
N/A
2.58
Revenue
$655,353,000.00
$1,123,479,000.00
Revenue This Year
$7.72
N/A
Revenue Next Year
$6.74
N/A
P/E Ratio
N/A
$3.47
Revenue Growth
8.28
64.69
52 Week Low
$9.82
$5.01
52 Week High
$20.05
$11.85

Technical Indicators

Market Signals
Indicator
NVCR
NVAX
Relative Strength Index (RSI) 38.59 38.12
Support Level $10.86 $8.01
Resistance Level $14.11 $9.05
Average True Range (ATR) 0.53 0.54
MACD -0.15 -0.23
Stochastic Oscillator 0.52 1.81

Price Performance

Historical Comparison
NVCR
NVAX

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: